University of Alabama at Birmingham
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Alabama at Birmingham sits in the top decile of US sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count).
University of Alabama at Birmingham: 1,160 sponsored US clinical trials, 216 recruiting.
University of Alabama at Birmingham sponsors 1,160 registered US clinical trials on ClinicalTrials.gov, 216 of them currently recruiting, and 723 completed. 97 of these trials are in Phase 3-4 (later-stage) and 259 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
University of Alabama at Birmingham ranks in the top decile of sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
723 of 812 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,160 total, page 2 of 24
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
NCT06294548
Establishment of an Interdisciplinary Functional Neurological Disorder (FND) Treatment Program and Development of a Clinical Care Pathway for FND
NCT06362161
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
NCT06867822
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
NCT07044544
Sequence of Midurethral Sling Placement During Robotic Sacrocolpopexy
NCT07008898
Brain Research Assessing Impacts of Neurophysiological Processing Speed Training in Veterans
NCT06217575
Housing, Environment, And Living Conditions for Transformed Health
NCT06925373
Pumping to Up Maternal Milk Production for Preterms
NCT06673160
Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women
NCT06360536
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
NCT06364917
Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease
NCT06989320
Time-restricted Eating for Postpartum Weight Loss
NCT06491537
Effects of Exogenous Ketones on Cognitive Function in Older Adults With Prediabetes?
NCT07546409
Adapting a Stress Management Intervention to Reduce Cardiovascular Disease Risk
NCT06811896
An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
NCT06326476
Comparison of Healing Measures Tibial Fractures Following Standard Intramedullary Nailing or Micromotion Tibial Intramedullary Nailing
NCT06679049
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
NCT06047886
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
NCT06315309
Wavelength Intervention for Nearsighted Kids
NCT06598423
Retraining and Control Therapy (ReACT)- Adults
NCT06570954
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
NCT06943586
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
NCT06265584
CGM for Management of Type 2 Diabetes in Pregnancy
NCT06628453
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
NCT06857006
Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
NCT06829238
The Effects of Virtual Reality Greenspace on Stress Among Adults With Mobility Impairments
NCT06682143
Sleep Intervention and Quality of Life in Down Syndrome
NCT06783725
African Americans (AA) Communities Speak
NCT05908487
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
NCT05952453
Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
NCT06105684
A Bundled Intervention
NCT06593093
Evaluating the Implementation and Impact of Standard-of-care Delivered Oncology Financial Navigation
NCT07281287
ACT for HIV-Positive Men
NCT06625437
Minority Stress Counseling for LGBTQ+ Individuals
NCT06614868
Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment
NCT06104280
Effect of a DASH-Style Diet on Urinary Risk Factors for Kidney Stone Disease
NCT06210009
Testimonials and Navigation in Rheumatology
NCT06469788
RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE
NCT06455085
A Telehealth Intervention to Increase Patient Preparedness for Surgery in Latinas
NCT06679621
Infant-Maternal Partnership and Cognitive Training Study for Preterm Infants
NCT06335524
The Presence of a Therapy Dog Reduces Pain and Anxiety During Pediatric Elbow Pin Removal
NCT05830201
A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
NCT06173323
Study of Tazemetostat in Lymphoid Malignancies
NCT05983965
The Fit With Us Study
NCT06207084
Improve Cancer-related Cognitive Impairment
NCT05864274
Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)
NCT06289582
Evaluation of Free Gingival Graft Timing
NCT06294587
Providing an Optimized and Empowered Pregnancy for You (POPPY) Aim 3: Randomized Controlled Trial
NCT06510075
Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.
NCT06253117
Improving Gout Care After an ED Visit
NCT06534554
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 129 |
| Phase 2 | 130 |
| Phase 3 | 25 |
| Phase 4 | 72 |
Therapeutic Areas
What is open in the University of Alabama at Birmingham pipeline
216 recruiting of 1,160 indexed (19% open); 723 completed (62%).
Phase mix: 97 late (III/IV) vs 259 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Alabama at Birmingham: open-pipeline peers nationwide
Peers matched on 1,160 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,160 trials (± recruiting share)
- NYU Langone Health · 1,164 trials · 17% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 19% open enrollment (± trial volume)
- University of Minnesota · 19% recruiting · 966 trials
- Mclean Hospital · 19% recruiting · 140 trials
- Children's Hospital Medical Center, Cincinnati · 19% recruiting · 571 trials
- Arkansas Children's Hospital Research Institute · 19% recruiting · 97 trials
Related
What to do with this University of Alabama at Birmingham page
1,160 registered trials is a research-attention snapshot, not an endorsement of University of Alabama at Birmingham or any single study.
- 216 of University of Alabama at Birmingham's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition University of Alabama at Birmingham studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Alabama at Birmingham pipeline card: 1,160 registered trials from official public datasets.Report a data error.